Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

36 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Teriflunomide and Time to Clinical Multiple Sclerosis in Patients With Radiologically Isolated Syndrome: The TERIS Randomized Clinical Trial.
Lebrun-Frénay C, Siva A, Sormani MP, Landes-Chateau C, Mondot L, Bovis F, Vermersch P, Papeix C, Thouvenot E, Labauge P, Durand-Dubief F, Efendi H, Le Page E, Terzi M, Derache N, Bourre B, Hoepner R, Karabudak R, De Seze J, Ciron J, Clavelou P, Wiertlewski S, Turan OF, Yucear N, Cohen M, Azevedo C, Kantarci OH, Okuda DT, Pelletier D; TERIS Study Group. Lebrun-Frénay C, et al. Among authors: turan of. JAMA Neurol. 2023 Oct 1;80(10):1080-1088. doi: 10.1001/jamaneurol.2023.2815. JAMA Neurol. 2023. PMID: 37603328 Free article. Clinical Trial.
Prevalence of and risk factors for cognitive impairment in patients with relapsing-remitting multiple sclerosis: Multi-center, controlled trial.
Ozakbas S, Turkoglu R, Tamam Y, Terzi M, Taskapilioglu O, Yucesan C, Baser HL, Gencer M, Akil E, Sen S, Turan OF, Sorgun MH, Yigit P, Turkes N. Ozakbas S, et al. Among authors: turan of. Mult Scler Relat Disord. 2018 May;22:70-76. doi: 10.1016/j.msard.2018.03.009. Epub 2018 Mar 24. Mult Scler Relat Disord. 2018. PMID: 29605801
Comparative analysis of fingolimod versus teriflunomide in relapsing-remitting multiple sclerosis.
Boz C, Terzi M, Özer B, Turkoglu R, Karabudak R, Efendi H, Soysal A, Sevim S, Altintas A, Kurne A, Akçalı A, Akman G, Yüceyar N, Balcı BP, Ekmekci Ö, Karahan SZ, Demirkıran M, Altunrende B, Turan ÖF, Gökçen GözübatıkÇelik, Kale N, Köseoğlu M, Ozakbas S. Boz C, et al. Among authors: turan of. Mult Scler Relat Disord. 2019 Nov;36:101376. doi: 10.1016/j.msard.2019.101376. Epub 2019 Aug 26. Mult Scler Relat Disord. 2019. PMID: 31473488
A 12-month, Open Label, Multicenter Pilot Study Evaluating Fingolimod Treatment in terms of Patient Satisfaction in Relapsing Remitting Multiple Sclerosis Patients - FINE Trial.
Demır GA, Türkoğlu R, Saıp S, Yüceyar N, Efendı H, Turan ÖF, Ağan K, Terzı M, Boz C, Tuncer A, Koçer B, Kasap M, Çalişkan Z; Fine Study Group. Demır GA, et al. Among authors: turan of. Noro Psikiyatr Ars. 2017 Jun 22;56(4):253-257. doi: 10.5152/npa.2017.20515. eCollection 2019 Dec. Noro Psikiyatr Ars. 2017. PMID: 31903032 Free PMC article.
Differences Between General Neurologists and Multiple Sclerosis Specialists in the Management of Multiple Sclerosis Patients: A National Survey.
Kürtüncü M, Tuncer A, Uygunoğlu U, Çalişkan Z, Paksoy AK, Efendı H, Kocaman AS, Özcan C, Terzı M, Turan ÖF, Saıp S, Karabudak R, Sıva A. Kürtüncü M, et al. Among authors: turan of. Noro Psikiyatr Ars. 2017 Jun 20;56(4):269-272. doi: 10.5152/npa.2017.19387. eCollection 2019 Dec. Noro Psikiyatr Ars. 2017. PMID: 31903035 Free PMC article.
The outcome of a national MS-Covid-19 study: What the Turkish MS cohort reveals?
Sen S, Karabudak R, Schiavetti I, Demir S, Ozakbas S, Tutuncu M, Petek Balci B, Turan OF, Uzunkopru C, Koseoglu M, Yetkin MF, Gunduz T, Gumus H, Kale Icen N, Carmisciano L, Terzi M, Acar P, Gungor Dogan I, Baba C, Tuncer A, Uygunoglu U, Sormani MP, Efendi H, Siva A; Turkish MS Study Group. Sen S, et al. Among authors: turan of. Mult Scler Relat Disord. 2021 Jul;52:102968. doi: 10.1016/j.msard.2021.102968. Epub 2021 Apr 18. Mult Scler Relat Disord. 2021. PMID: 33940495 Free PMC article.
The Turkish experience of COVID-19 infection in people with NMOSD and MOGAD: A milder course?
Sen S, Tuncer A, Ozakbas S, Uzunkopru C, Baba C, Demir S, Beckmann Y, Gumus H, Arslan G, Kilic AK, Altintas A, Yuceyar N, Turan OF, Tutuncu M, Terzi M, Acar P, Bunul SD, Balci BP, Bir LS, Koseoglu M, Mungan S, Gunduz T, Dogan IG, Kotan D, Uygunoglu U, Ekmekci O, Demirkiran M, Kamisli O, Kabay SC, Tamam Y, Omerhoca S, Sevim S, Guler S, Kurtuncu M, Efendi H, Karabudak R, Siva A. Sen S, et al. Among authors: turan of. Mult Scler Relat Disord. 2022 Feb;58:103399. doi: 10.1016/j.msard.2021.103399. Epub 2021 Nov 19. Mult Scler Relat Disord. 2022. PMID: 35216782 Free PMC article.
The comparative effectiveness of fingolimod, natalizumab, and ocrelizumab in relapsing-remitting multiple sclerosis.
Boz C, Ozakbas S, Terzi M, Karabudak R, Sevim S, Turkoglu R, Soysal A, Balcı BP, Efendi H, Turan ÖF, Yüceyar N, Yetkin MF, Karahan SZ, Demirkıran M, Guler S, Agan K, Kıylıoğlu N, Baba C, Tuncer A, Köseoğlu M. Boz C, et al. Among authors: turan of. Neurol Sci. 2023 Jun;44(6):2121-2129. doi: 10.1007/s10072-023-06608-z. Epub 2023 Jan 23. Neurol Sci. 2023. PMID: 36689010
Retrospective analysis of effectiveness of fingolimod in real life setting in Turkey (REFINE).
Tuncer MA, Kürtüncü M, Terzi M, Uygunoğlu U, Göncüoğlu C, Yüceyar AN, Ekmekçi Ö, Türkoğlu R, Soysal A, Köseoğlu M, Boz C, Beckmann Y, Turan ÖF, Demirkıran DM, Akman FG, Altunrende B, Cantürk İA, Birday E, Özcan A, Kamişli Ö, Özen NPA, Çelik RGG, Balcı FB, Efendi H, Sarıkaya C, Akçalı A, Toprak MK, Kabay SC, Kızılay F, Sevim MS, Gazaloğlu GB, Demir CF, Balgetir F, Kıylıoğlu N, Sarıahmetoğlu H, Ölmez Ç, Mavi K, Yüksel S, Işık N, Saip S, Karabudak R, Siva A, Eraksoy M. Tuncer MA, et al. Among authors: turan of. Turk J Med Sci. 2023 Feb;53(1):323-332. doi: 10.55730/1300-0144.5588. Epub 2023 Feb 22. Turk J Med Sci. 2023. PMID: 36945929 Free PMC article.
36 results